Phospho erk1 2 4370

Manufactured by Cell Signaling Technology

Sourced in France

Phospho-Erk1/2 (4370) is a primary antibody product from Cell Signaling Technology. It is designed to detect endogenous levels of Erk1 and Erk2 when phosphorylated at specific tyrosine and threonine residues.

Automatically generated - may contain errors

Lab products found in correlation

Ab102842, by Abcam (1 mentions) Lipofectamine rnaimax, by Thermo Fisher Scientific (1 mentions) Dmem f12, by Thermo Fisher Scientific (1 mentions) β actin antibody a5316, by Merck Group (1 mentions) Trypsin, by Thermo Fisher Scientific (1 mentions) Lamp 1 9091, by Cell Signaling Technology (1 mentions) U0216, by Cell Signaling Technology (1 mentions) Erk1 2 4695, by Cell Signaling Technology (1 mentions)

Spelling variants of this product

ERK1/2 (1487 citations) Phospho-ERK1/2 (582 citations) Anti-phospho-ERK1/2 #4370 (5 citations) Anti- Phospho-p44/42 MAPK (Erk1/2) (4370 (2 citations) Phospho-p44/42 MAPK ERK1/2 (4370; (2 citations) Phospho-Erk1/2 (Thr202/Tyr204; 4370 (2 citations) Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (2 citations)

2 protocols using phospho erk1 2 4370

Recombinant Expression of BMI1 and DEFA5

Check if the same lab product or an alternative is used in the 5 most similar protocols

Complementary DNAs (cDNA) for human BMI1 and DEFA5 were amplified from reverse‐transcribed cDNA of HEK293T cells. For recombinant expression in E coli, the cDNA of DEFA5 was cloned into a modified RSF‐Duet vector with an N‐terminal 6× His‐tag and BMI1 was inserted into a pGEX‐6p‐1 vector. cDNAs of human DEFA5 were inserted into the pCDH vector for lentivirus packaging in HEK293T cells. All plasmids were verified using DNA sequencing.
Antibodies for AKT (4691), Phospho‐AKT (4060), Erk1/2 (4695), and Phospho‐Erk1/2 (4370) were obtained from Cell Signaling Technology. Anti‐DEFA5 (ab180515), anti‐BMI1 (ab126783), anti‐p16 (ab51243), anti‐PTEN (ab267787), anti‐Spry‐2 (ab180527), anti‐E‐cadherin (ab40772) and anti‐p19 (ab102842) antibodies were obtained from Abcam. Anti‐HA (H3663) tag and anti‐β‐actin (A5441) antibody was obtained from Sigma‐Aldrich.

Wu Z., Ding Z., Cheng B, & Cui Z. (2021). The inhibitory effect of human DEFA5 in growth of gastric cancer by targeting BMI1. Cancer Science, 112(3), 1075-1083.

+ Open protocol

+ Expand

Dox Resistance in MCF-7 Breast Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

MCF-7, a human breast carcinoma cell line derived from the pleural effusion metastasis, weas purchased from ATCC (USA). Dox was purchased from Farmitalia (Italy). MCF-7 resistant cells (MCF-7R) were obtained from MCF-7 parental cells by increased Dox treatment. DMEM/F-12, trypsin and Lipofectamine RNAiMAX were from Invitrogen (France). Bovine fetal serum was from Dutscher (France). LRP-1 polyclonal antibody ‘ab92544’ was from Abcam (France). Caspase-7 ‘#9492’, ERK 1/2 ‘#4695’, Phospho-ERK 1/2 ‘#4370’, LAMP-1 ‘#9091’ and P-gp ‘#13342’ antibodies were from Cell Signaling Technology (France). LRP-1 siRNA kit ‘sc-40101’ was purchased from Santa Cruz Biotechnology (USA). Kit ECL was from Amersham (Germany). U0216, a elective inhibitor of MEK-1 and MEK-2, was from Cell Signaling Technology (France). UptiBlue and BCA kit ‘23225’ were from Uptima (Thermofisher, France). CaspACE assay kit ‘G8091’ was from Promega (France). β-actin antibody ‘A5316’, invertase enzyme ‘I9274’ and all other reagents were from Sigma (USA). Histidine-tagged RAP was purified as previously described [41 (link)] and used as an antagonist of LRP-1-dependent endocytosis [41 (link), 42 (link)].

Henry A., Mauperin M., Devy J., Dedieu S., Chazee L., Hachet C., Terryn C., Duca L., Martiny L., Devarenne-Charpentier E, & Btaouri H.E. (2023). The endocytic receptor protein LRP-1 modulate P-glycoprotein mediated drug resistance in MCF-7 cells. PLOS ONE, 18(9), e0285834.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!